{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"groups":[{"description":"Patients receive azacitidine SC or IV on days 1-7. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.\n\nazacitidine: Given SC or IV\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Chemotherapy)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"6 months","title":"Incidence of Grades II-IV Graft-versus-host Disease (GVHD)","type":"SECONDARY","unitOfMeasure":"Participants"}